Go Pro
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.42
+3.1%		$0.58
$0.38
▼
$15.00
$66.98M-0.162,869 shs9,459 shs
iBio, Inc. stock logo
IBIO
iBio
$1.39
-0.7%		$1.58
$0.56
▼
$3.82
$69.55M1.3770,004 shs423,551 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$0.65
-2.1%		$0.57
$0.32
▼
$3.14
$18.48M3.023.21 million shs650,921 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.54
-2.2%		$1.58
$1.34
▼
$3.35
$63.67M0.04141,564 shs109,483 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+1.54%-8.52%-30.60%-51.74%+40,249,900.00%
iBio, Inc. stock logo
IBIO
iBio
-4.11%+2.94%-13.58%-14.63%+139,999,900.00%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-1.51%+9.97%+41.61%-27.36%-77.86%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-4.27%-4.27%-2.48%-3.09%-50.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.42
+3.1%		$0.58
$0.38
▼
$15.00
$66.98M-0.162,869 shs9,459 shs
iBio, Inc. stock logo
IBIO
iBio
$1.39
-0.7%		$1.58
$0.56
▼
$3.82
$69.55M1.3770,004 shs423,551 shs
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
$0.65
-2.1%		$0.57
$0.32
▼
$3.14
$18.48M3.023.21 million shs650,921 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.54
-2.2%		$1.58
$1.34
▼
$3.35
$63.67M0.04141,564 shs109,483 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
+1.54%-8.52%-30.60%-51.74%+40,249,900.00%
iBio, Inc. stock logo
IBIO
iBio
-4.11%+2.94%-13.58%-14.63%+139,999,900.00%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-1.51%+9.97%+41.61%-27.36%-77.86%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-4.27%-4.27%-2.48%-3.09%-50.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
iBio, Inc. stock logo
IBIO
iBio
3.13
Buy$5.00259.71% Upside
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.38
Hold$12.001,757.30% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67269.16% Upside

Current Analyst Ratings Breakdown

Latest JSPR, IBIO, ALPS, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
7/6/2026
ALPS
ALPS Group Inc Ordinary Share
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/2/2026
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
6/24/2026
iBio, Inc. stock logo
IBIO
iBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/8/2026
iBio, Inc. stock logo
IBIO
iBio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$5.00
6/8/2026
iBio, Inc. stock logo
IBIO
iBio
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$5.00
6/5/2026
iBio, Inc. stock logo
IBIO
iBio
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$6.00
5/15/2026
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetSector Perform$4.00 ➝ $3.00
5/15/2026
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
N/AN/A$0.19 per share2.19($3.10) per shareN/A
iBio, Inc. stock logo
IBIO
iBio
$400K172.64N/AN/A$0.90 per share1.54
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/A$0.15 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$980K$0.331.26N/AN/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
-$18.38M-$0.58N/AN/AN/AN/A-53.86%-46.48%9/4/2026 (Estimated)
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$75.80M-$3.23N/AN/AN/AN/A-613.51%-162.52%8/12/2026 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)

Latest JSPR, IBIO, ALPS, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$0.38N/AN/AN/AN/AN/A
8/10/2026Q4 2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$0.04N/AN/AN/AN/AN/A
8/6/2026Q4 2026
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A$1.33 million
5/14/2026Q1 2026
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
-$0.46-$0.38+$0.08-$0.04N/AN/A
5/12/2026Q3 2026
iBio, Inc. stock logo
IBIO
iBio
-$0.06-$0.07-$0.01-$0.06$0.02 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/A
11.88
11.88
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
N/A
2.26
2.26
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
iBio, Inc. stock logo
IBIO
iBio
7.90%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
79.85%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
25.52%
iBio, Inc. stock logo
IBIO
iBio
2.75%
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2.30%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
N/A166.40 million123.94 millionN/A
iBio, Inc. stock logo
IBIO
iBio
10049.68 million48.31 millionN/A
Jasper Therapeutics, Inc. stock logo
JSPR
Jasper Therapeutics
2028.00 million27.35 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
740.56 million24.15 millionNot Optionable

Recent News About These Companies

OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday
August 3 at 11:10 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-okyo-expected-to-post-quarterly-earnings-on-monday-2026-08-03/
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334117/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-scientific-officer.html
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333362/0/en/okyo-pharma-to-participate-in-the-btig-biotechnology-conference-2026.html
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain
July 25, 2026  |  ophthalmologytimes.comO
OKYO Pharma Announces Purchase of Shares by Director
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3332413/0/en/okyo-pharma-announces-purchase-of-shares-by-director.html
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
July 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/23/3331994/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-executive-officer.html
OKYO Pharma Announces Purchase of Shares by Chairman
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331587/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-development-officer-and-director.html
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
July 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/22/3331223/0/en/okyo-pharma-announces-purchase-of-shares-by-chief-medical-officer.html
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/okyo-pharma-to-present-at-the-h-c-wainwright-6th-annual-ophthalmology-virtual-conference-1036345995
OKYO Pharma Announces Purchase of Shares by Chairman
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330300/0/en/okyo-pharma-announces-purchase-of-shares-by-chairman.html
Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095724?snapi
OKYO Pharma (NASDAQ:OKYO) Posts Earnings Results, Misses Estimates By $5.45 EPS
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-nasdaqokyo-posts-earnings-results-misses-estimates-by-545-eps-2026-07-20/
OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans
July 20, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095701?snapi
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329597/0/en/okyo-pharma-announces-filing-of-annual-report-with-strengthened-cash-position-and-accelerated-phase-3-plans.html
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Average Rating of "Hold" from Brokerages
July 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/okyo-pharma-limited-sponsored-adr-nasdaqokyo-receives-average-rating-of-hold-from-brokerages-2026-07-20/
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium
July 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OKYO/pressreleases/3181476/okyo-pharma-to-highlight-neuropathic-corneal-pain-program-at-piper-sandler-virtual-ophthalmology-symposium/
Q3 Earnings Estimate for OKYO Pharma Issued By HC Wainwright
July 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/q3-earnings-estimate-for-okyo-pharma-issued-by-hc-wainwright-2026-07-14/
OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP
July 11, 2026  |  pharmabiz.comP
OKYO Pharma advances toward Phase 3 FDA trial - ICYMI
July 11, 2026  |  proactiveinvestors.comhttps://www.proactiveinvestors.com/companies/news/1095285?snapi
Phase 3 trial to study urcosimod in neuropathic corneal pain
July 10, 2026  |  healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.42 +0.01 (+3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$0.41 0.00 (-0.24%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

iBio stock logo

iBio NASDAQ:IBIO

$1.39 -0.01 (-0.71%)
Closing price 04:00 PM Eastern
Extended Trading
$1.39 0.00 (0.00%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

Jasper Therapeutics stock logo

Jasper Therapeutics NASDAQ:JSPR

$0.65 -0.01 (-2.09%)
Closing price 04:00 PM Eastern
Extended Trading
$0.66 +0.01 (+2.00%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.54 -0.04 (-2.23%)
Closing price 03:59 PM Eastern
Extended Trading
$1.54 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas